Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

10.73
+0.01500.14%
Volume:100.09K
Turnover:1.07M
Market Cap:1.04B
PE:-6.32
High:10.83
Open:10.72
Low:10.53
Close:10.71
52wk High:14.93
52wk Low:3.90
Shares:97.39M
Float Shares:60.66M
Volume Ratio:0.89
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6957
EPS(LYR):-1.8335
ROE:-39.73%
ROA:-25.23%
PB:2.57
PE(LYR):-5.85

Loading ...

Oric Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employees

Reuters
·
Feb 07

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 07

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 07

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Feb 06

Oric Pharmaceuticals Director Richard A. Heyman Reports Sale of Common Shares

Reuters
·
Jan 21

ORIC Pharmaceuticals: Dense Near‑Term Clinical Catalysts and Encouraging Efficacy Data Underpin Reiterated Buy Rating

TIPRANKS
·
Jan 15

Wedbush Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Jan 13

Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush

Dow Jones
·
Jan 13

Oric Pharmaceuticals Raises $244 Million in Private Placement

Reuters
·
Jan 12

Oric Pharmaceuticals Appoints Kevin Brodbeck as Chief Technical Officer

Reuters
·
Jan 12

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

GlobeNewswire
·
Jan 12

Oric Pharmaceuticals Initiated at Overweight by Piper Sandler

Dow Jones
·
Jan 07

Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target

MT Newswires Live
·
Jan 07

ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 07

BUZZ-India's Orient Technologies rises after shareholders approve bonus issue

Reuters
·
Dec 30, 2025

Oric Pharmaceuticals Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since June 2024 -- Data Talk

Dow Jones
·
Dec 17, 2025

ORIC Pharmaceuticals (ORIC): Valuation Check After Encouraging Enozertinib Phase 1b Lung Cancer Data

Simply Wall St.
·
Dec 09, 2025

Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush

Dow Jones
·
Dec 08, 2025

Oric Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employees

Reuters
·
Dec 06, 2025

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 06, 2025